Amrinone

Amrinone
Clinical data
Trade names	Inocor
Other names	inamrinone (USAN US)
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	C01CE01 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	n/a
Protein binding	10 to 49%
Metabolism	Hepatic
Elimination half-life	5 to 8 hours
Excretion	Renal (63%) and fecal (18%)
Identifiers
	IUPAC name 5-amino-3,4'-bipyridin-6(1H)-one;
CAS Number	60719-84-8 ;
PubChem CID	3698;
IUPHAR/BPS	7202;
DrugBank	DB01427 ;
ChemSpider	3570 ;
UNII	JUT23379TN;
KEGG	D00231 ;
ChEBI	CHEBI:2686;
ChEMBL	ChEMBL12856 ;
CompTox Dashboard (EPA)	DTXSID9022603 ;
ECHA InfoCard	100.056.700
Chemical and physical data
Formula	C10H9N3O
Molar mass	187.202 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2C(/N)=C\C(\c1ccncc1)=C/N2;
	InChI InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14) ; Key:RNLQIBCLLYYYFJ-UHFFFAOYSA-N ;
	(verify)

Amrinone, also known as inamrinone, and sold as Inocor, is a pyridine phosphodiesterase 3 inhibitor.^[1] It is a drug that may improve the prognosis in patients with congestive heart failure.^[2] Amrinone has been shown to increase the contractions initiated in the heart by high-gain calcium induced calcium release (CICR).^[3] The positive inotropic effect of amrinone is mediated by the selective enhancement of high-gain CICR, which contributes to the contraction of myocytes by phosphorylation through cAMP dependent protein kinase A (PKA) and Ca²⁺ calmodulin kinase pathways.^[3]

^ Hamada Y, Kawachi K, Yamamoto T, Nakata T, Kashu Y, Sato M, Watanabe Y (August 1999). "Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone". Japanese Circulation Journal. 63 (8): 605–609. doi:10.1253/jcj.63.605. PMID 10478810.
^ Cite error: The named reference AJC.1981.48 was invoked but never defined (see the help page).
^ ^a ^b Xiong W, Ferrier GR, Howlett SE (August 2004). "Diminished inotropic response to amrinone in ventricular myocytes from myopathic hamsters is linked to depression of high-gain Ca2+-induced Ca2+ release". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 761–773. doi:10.1124/jpet.103.064873. PMID 15064331. S2CID 6036283.

[pmid10478810-1] Hamada Y, Kawachi K, Yamamoto T, Nakata T, Kashu Y, Sato M, Watanabe Y (August 1999). "Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone". Japanese Circulation Journal. 63 (8): 605–609. doi:10.1253/jcj.63.605. PMID 10478810.

[AJC.1981.48-2] Cite error: The named reference AJC.1981.48 was invoked but never defined (see the help page).

[JPET.2004-3] Xiong W, Ferrier GR, Howlett SE (August 2004). "Diminished inotropic response to amrinone in ventricular myocytes from myopathic hamsters is linked to depression of high-gain Ca2+-induced Ca2+ release". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 761–773. doi:10.1124/jpet.103.064873. PMID 15064331. S2CID 6036283.

[1]

[2]

[3]